Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients.

Abstract

BACKGROUND:

The aim of this study was to investigate the clinical efficacy of RetroNectin-activated cytokine-induced killer cell (R-CIK) therapy following conventional therapies in patients with metastatic brain tumors.

METHODS:

This study included 20 patients with metastatic brain tumors. Patients received R-CIK therapy following conventional therapies (including chemotherapy and target therapy). Progression-free survival (PFS), overall survival (OS), and prognostic factors were evaluated.

RESULTS:

Of the 4 breast cancer patients in our cohort, 2 remained alive and 2 died. Of the 14 non-small cell lung cancer (all adenocarcinoma) patients, 3 had a partial response, 8 had stable disease, and 3 had progressive disease after receiving R-CIKs. The overall response rate was 21.4% (3/14), and the disease control rate was 78.6% (11/14). The median PFS and OS were 7.7 months (95% confidence interval (CI) 3-16.5 months) and 12.6 months (95% CI 6-21 months), respectively.

CONCLUSION:

R-CIKs combined with conventional therapies could improve the prognosis of metastatic brain tumor patients, especially of those with adenocarcinoma of the lung.

• Authors: Wei Li, Yaomei Wang, Lingdi Zhao, Linping Xu, Yong Zhang, Ling Mai, Quanli Gao
• Journal: Oncology research and treatment (Oncol Res Treat) Vol. 38 Issue 4 Pg. 160-5 ( 2015) ISSN: 2296-5262 [Electronic] Switzerland
• PMID: 25877939 (Publication Type: Case Reports, Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2015 S. Karger GmbH, Freiburg.

Chemical References

• Fibronectins
• Recombinant Proteins
• retronectin

Topics

• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Brain Neoplasms (immunology, pathology, secondary, therapy)
• Carcinoma, Renal Cell (immunology, pathology, secondary, therapy)
• Combined Modality Therapy
• Cytokine-Induced Killer Cells (drug effects, immunology)
• Cytotoxicity Tests, Immunologic
• Disease Progression
• Female
• Fibronectins (adverse effects, therapeutic use)
• Humans
• Immunotherapy, Adoptive (methods)
• Kidney Neoplasms (immunology, pathology, therapy)
• Male
• Middle Aged
• Recombinant Proteins (adverse effects, therapeutic use)
• Treatment Outcome